Sagimet Biosciences Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
155 BOVET RD., SUITE 303, SAN MATEO, CA, 94402
Mailing Address
155 BOVET RD., SUITE 303, SAN MATEO, CA, 94402
Phone
(650) 561-8600
Fiscal Year End
1231
EIN
205991472
Financial Overview
FY2025
$160.26M
Total Assets
$75.84M
Cash & Equivalents
$-1.45
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 20, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
Annual Reports
10-K
March 11, 2026
- Successfully completed Phase 2b FASCINATE-2 clinical trial for denifanstat in MASH with positive top-line results, significantly de-risking the lead asset.
- Increased cash and cash equivalents to $155.0 million as of December 31, 2025, extending cash runway into late 2027.
Insider Trading
SELL
5 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.